Leaky Gut and Intestinal Permeability: Separating Evidence from Speculation
Intestinal hyperpermeability is a real, measurable physiological phenomenon studied in peer-reviewed literature. Here's what the evidence supports — and where 'leaky gut' narratives substantially outpace the science.
This article is intended for health professionals and informed practitioners. It does not constitute individual medical advice. The term "leaky gut" is not a recognised medical diagnosis. Where intestinal permeability is clinically relevant, it requires interpretation within the context of established pathology and appropriate investigation.
"Leaky gut" is simultaneously one of the most discussed concepts in functional and integrative medicine and one of the most contested in mainstream gastroenterology. The divide is not simply ideological. The underlying science — intestinal permeability — is legitimate, actively researched, and published in peer-reviewed journals. The problem is the clinical leap: the extrapolation from a real physiological mechanism to a vast catalogue of conditions, often before the evidence supports it.
This article maps what is actually established in the research literature, where the evidence remains preliminary, and where widely circulating claims have moved substantially ahead of the science. For practitioners ordering permeability investigations or interpreting commercial tests, understanding that distinction is essential.
The Biology of the Intestinal Barrier
The gut is not simply a passive tube. The intestinal epithelium is a selective barrier with extraordinary structural sophistication, designed to absorb nutrients while restricting the passage of microbes, toxins, and large antigenic molecules.
The primary structural components of this barrier include:
Tight junctions are protein complexes that seal the space between adjacent enterocytes — the absorptive cells lining the gut wall. The major tight junction proteins include zonula occludens-1 (ZO-1), occludin, and the claudin family. These proteins form a dynamic, regulatable seal: they are not simply open or closed, but modulated continuously by luminal contents, immune signals, and neural input. The integrity of tight junctions is the central mechanism in most discussions of intestinal permeability.
Transcellular transport via transcytosis allows some molecules to pass through — rather than between — enterocytes. This is a normal physiological process, including for secretory IgA recycling, but can become dysregulated under inflammatory conditions.
The mucus layer is produced by goblet cells interspersed throughout the epithelium. This two-layered gel (particularly in the colon) provides a physical buffer between luminal bacteria and the epithelial surface. Thinning of the mucus layer — as seen in ulcerative colitis — is associated with increased bacterial contact with the epithelium and, in turn, permeability changes.
Secretory IgA (SIgA) operates in the gut lumen as the primary mucosal immunoglobulin, binding pathogens and toxins before they can interact with the epithelial surface. SIgA deficiency is associated with increased susceptibility to gut infection and, in some studies, increased permeability.
A frequently underappreciated point: the gut epithelium turns over completely every three to five days. This remarkable regenerative capacity means that insults causing epithelial damage — while clinically significant — are often reversible once the driving cause is removed.
What "Increased Permeability" Actually Means
"Leaky gut" is colloquial shorthand for intestinal hyperpermeability — a measurable increase in the passage of molecules across the gut wall, particularly via the paracellular route (between cells).
When tight junctions loosen, larger molecules gain access to the lamina propria, the connective tissue layer beneath the epithelium. These molecules include:
- Lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls and a potent activator of the innate immune system via Toll-like receptor 4 (TLR4)
- Food-derived antigens (including partially digested peptides)
- Bacterial fragments and endotoxins
Once in the lamina propria, these molecules can trigger localised and systemic immune responses. The degree to which this drives disease — versus being a consequence of existing disease — is one of the core contested questions in the field.
How Permeability Is Measured
The lactulose:mannitol (L:M) ratio is the research gold standard. Subjects drink a solution containing lactulose (a large disaccharide) and mannitol (a small monosaccharide). Mannitol is absorbed transcellularly; lactulose is not normally absorbed. An increased ratio in urine indicates paracellular leak of the larger molecule — i.e., tight junction disruption. This test is validated, reproducible, and used extensively in clinical research.
FITC-dextran assays are used extensively in animal models and some human research. Fluorescently labelled dextran molecules of defined molecular weights are administered and detected in blood, providing a direct measure of translocation. It is a standard laboratory tool but less practical for routine clinical use.
Serum zonulin is the commercially available biomarker offered by various functional testing laboratories. The story of zonulin is instructive about the gap between scientific development and commercial translation. Zonulin was characterised by Alessio Fasano and colleagues as an endogenous regulator of tight junctions, triggered by gliadin and bacterial exposure. The concept is valid. However, the commercial ELISA assay does not measure zonulin-1 (haptoglobin 2, the protein Fasano's group originally described) specifically — it detects a mixture of related proteins. This cross-reactivity means serum zonulin values from commercial kits do not reliably map to research findings that used more specific assays.
In practical terms: a positive commercial zonulin result is not a diagnosis of increased intestinal permeability, and clinical interpretation should be appropriately cautious. A 2020 review in Nutrients by Vanuytsel and colleagues, among others, has specifically noted the discordance between commercial zonulin assays and functional permeability tests.
Where Intestinal Permeability Is Established
The following conditions have strong, replicated evidence linking them to measurable increases in intestinal permeability.
Coeliac disease is the most mechanistically characterised example. Gliadin (the alcohol-soluble fraction of gluten) activates the zonulin signalling pathway, leading to displacement of ZO-1 from tight junction complexes and measurable increases in paracellular permeability. This mechanism is well-characterised through Fasano's work and replicated by multiple groups. Critically, permeability normalises on a strict gluten-free diet — demonstrating reversibility and confirming causation rather than mere association.
Inflammatory bowel disease — both Crohn's disease and ulcerative colitis — consistently shows elevated L:M ratios compared to healthy controls. In Crohn's disease, increased permeability has been demonstrated in unaffected relatives, suggesting it may precede inflammation rather than simply result from it. Whether permeability is a primary driver or a consequence of mucosal inflammation remains debated, but the finding itself is robust.
Sepsis and critical illness represent the most clinically severe form. Profound intestinal permeability during systemic inflammatory states allows bacterial translocation from the gut lumen into the systemic circulation, potentially amplifying sepsis. This is well-established in critical care medicine and underpins nutritional interventions — including early enteral feeding — in ICU settings.
Non-coeliac gluten sensitivity (NCGS) shows some evidence of increased permeability following gluten exposure in susceptible individuals, but the mechanistic picture is less clear than in coeliac disease. A study by Hollon and colleagues (2015) demonstrated that gliadin triggered increased permeability in both coeliac and NCGS tissue ex vivo, though the magnitude and clinical significance differed between groups.
Intensive endurance exercise produces a well-documented and predictable transient increase in permeability. The mechanism is splanchnic hypoperfusion — during maximal effort, blood is shunted away from the gut toward working muscles and the cardiopulmonary system, causing relative ischaemia of the intestinal wall and loosening of tight junctions. The increase is measurable by L:M ratio, reverses with recovery, and explains gastrointestinal complaints commonly reported by endurance athletes.
Chronic alcohol use damages tight junction proteins through multiple pathways including acetaldehyde toxicity, oxidative stress, and dysbiosis-mediated changes. LPS translocation from a permeable gut is a key mechanism in the pathogenesis of alcoholic liver disease — the gut-liver axis is one of the most evidence-supported examples of permeability having clinically meaningful systemic consequences.
Where the Evidence Is Weaker or Speculative
Several conditions are frequently discussed in functional medicine contexts in relation to leaky gut. The evidence base here is considerably more heterogeneous.
Autism spectrum disorder (ASD) and ADHD: Gastrointestinal symptoms are common in ASD, and some small studies have found elevated L:M ratios in ASD populations. However, the literature is inconsistent, study populations are small and heterogeneous, and methodological quality is variable. Increased permeability in this context may reflect dietary patterns, microbiome composition, or co-occurring GI conditions rather than being a mechanism of neurodevelopmental pathology. Conflating gut-brain axis research — a legitimate and active field — with a specific mechanistic claim about leaky gut driving ASD substantially overreads the available evidence.
Broad autoimmune disease: Association data between increased permeability and conditions including type 1 diabetes mellitus and multiple sclerosis exists in the literature. The "leaky gut causes autoimmunity" narrative that circulates in functional medicine is, however, reductive in two important respects: first, many patients with established autoimmune disease have normal permeability when tested; second, causation has not been demonstrated — shared environmental or dysbiosis-related triggers may independently produce both permeability and autoimmune activation without one causing the other.
Food sensitivities: The association between food reactivity and permeability is mechanistically plausible — if larger food antigens cross the epithelium, immune sensitisation could follow. Some studies have found correlations. However, measurement inconsistency between labs and studies, the absence of standardised case definitions for "food sensitivity," and substantial confounding make the evidence base difficult to interpret. Current evidence does not support using permeability testing as a primary diagnostic tool for food sensitivity.
What Actually Increases Intestinal Permeability
The evidence for causative agents varies considerably in quality.
Well-established: NSAIDs increase gut permeability in a dose-dependent manner via both COX-mediated and topical mechanisms — the L:M ratio change following NSAID administration is one of the most reproducible findings in the permeability literature. Chronic alcohol use, gliadin (in susceptible individuals), psychological stress (via the CRH → mast cell → tight junction disruption pathway), dysbiosis (particularly reduction in butyrate-producing Firmicutes such as Faecalibacterium prausnitzii and Roseburia intestinalis), and intensive exercise without adequate recovery are all supported by mechanistic and/or human clinical data.
Under-studied or mixed: Certain food additives — particularly emulsifiers including carboxymethylcellulose (CMC) and polysorbate 80 — have produced compelling results in animal models, including demonstrable effects on the mucus layer and tight junction proteins. Human trial data remain limited, but the precautionary concern is biologically plausible and the subject of active investigation.
Interventions with Evidence
Glutamine is the primary fuel source for enterocytes. In critically ill patients, intravenous and enteral glutamine supplementation reduces the L:M ratio and markers of bacterial translocation — this is among the better-supported nutritional interventions in critical care. Evidence in healthy populations or those with low-grade permeability is considerably weaker. Clinical trials in this space typically use 10–20 g/day ranges.
Butyrate is a short-chain fatty acid produced by colonic fermentation of dietary fibre by specific bacterial taxa. Butyrate upregulates tight junction protein expression (ZO-1, occludin) in vitro and in animal models, and some clinical trials support improvement in gut barrier function. The most evidence-based approach is dietary: increasing resistant starch, inulin-type fructans, and diverse fermentable fibre to support butyrate-producing bacteria, rather than relying solely on butyrate supplementation.
Zinc carnosine has specific RCT evidence in the context of NSAID-induced permeability. A randomised controlled trial by Rayner and colleagues demonstrated that zinc carnosine attenuated the increase in gut permeability caused by indomethacin, making it one of the more specifically evidence-matched interventions for a defined permeability context.
Probiotics: Specific strains — notably Lactobacillus rhamnosus GG and certain Bifidobacterium species — have shown reductions in permeability markers in IBS populations and post-antibiotic contexts in clinical trials. Critically, the evidence is strain-specific and cannot be generalised to probiotics as a class. Selection based on generic "probiotic" labelling without strain-level evidence is not supported by the research.
Removing offending agents remains the most evidence-based intervention where a causative trigger has been identified. Gluten removal in coeliac disease produces the most dramatic and well-characterised normalisation of permeability. Alcohol reduction, NSAID cessation, and addressing dysbiosis through targeted dietary change follow similar logic — treat the cause, and the epithelium's remarkable regenerative capacity does the rest.
A Note on Commercial Testing in Clinical Practice
Serum zonulin is now widely offered as a standalone biomarker for intestinal permeability assessment. Given the assay limitations described above, a measured approach is warranted.
A positive result should not be communicated to patients as confirmation of "leaky gut" as a disease entity. It may appropriately prompt further clinical investigation — including dietary history, medication review (especially NSAIDs), alcohol use history, dysbiosis assessment, and relevant exclusionary testing such as coeliac serology and IBD markers. Clinical context determines significance, not the number alone.
The L:M ratio, where available through research-grade laboratories, remains more reliable for assessing actual paracellular permeability but is impractical for most routine clinical settings.
Practitioners should also remain alert to conditions affecting intestinal permeability that fall firmly within the scope of conventional gastroenterology — including inflammatory bowel disease and coeliac disease — and ensure appropriate referral pathways are in place when these are clinically suspected.